Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719941 | 0.85 | KDM4E (0.42) | CYP11B1CYP11B2TRPV4DPP4DPP8 | |
| SCHEMBL21158608 | 0.84 | PTGDR2 (0.48) | PTGDR2ARMAOAMAOB | |
| SCHEMBL3164050 | 0.84 | CYP11B1 (0.58) | CYP11B1CYP11B2PTGDR2TRPV4AR | |
| SCHEMBL24872544 | 0.83 | TRPV4 (0.45) | CYP11B1CYP11B2TRPV4DPP4DPP8 | |
| SCHEMBL14663528 | 0.83 | AR (0.55) | CYP11B1CYP11B2PTGDR2ARMAOA | |
| SCHEMBL13179910 | 0.82 | TRPV4 (0.44) | CYP11B1CYP11B2TRPV4DPP4DPP8 | |
| SCHEMBL8156844 | 0.81 | MAOB (0.44) | CYP11B1CYP11B2TRPV4ARMAOA | |
| SCHEMBL15018389 | 0.80 | TRPV4 (0.42) | TRPV4DPP4DPP8ARMAOA | |
| SCHEMBL19437205 | 0.80 | TRPV4 (0.42) | TRPV4DPP4DPP8ARMAOA | |
| SCHEMBL51299 | 0.80 | LOXL2 (0.47) | TRPV4DPP4DPP8ARMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| WO-2024140850-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-11629135-B2 | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation | JUBILANT PRODELL LLC (US) | 2023-04-18 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| WO-2021197467-A1 | MULTI-TARGET ANTI-TUMOR COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海华汇拓医药科技有限公司 | 2021-10-07 | — | — | WO | disclosed |
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| EP-1040097-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20010036950-A1 | Potassium channel openers | CARROLL WILLIAM A (US) | 2001-11-01 | — | — | US | disclosed |
| US-6265417-B1 | MUSCLE RELAXANTS | ABBOTT LABORATORIES | 2001-07-24 | — | — | US | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1040097-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999031059-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | CYP11B1 1842/4885CYP11B2 2218/4885PTGDR2 1652/4885 |
| US-11629135-B2 | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation | PDCD1, CD274, PDCD1LG2 | CYP11B1 350/4885CYP11B2 949/4885PTGDR2 2769/4885 |
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | CYP11B1 350/4885CYP11B2 949/4885PTGDR2 2769/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | CYP11B1 1407/4885CYP11B2 2028/4885PTGDR2 3020/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | CYP11B1 2496/4885CYP11B2 2549/4885PTGDR2 404/4885 |
| US-20010036950-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | CYP11B1 735/4885CYP11B2 1040/4885PTGDR2 2511/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | CYP11B1 2496/4885CYP11B2 2549/4885PTGDR2 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.